Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$6.32 -7.5%	$6.35	$3.20 ▼ $7.84	$146.02M	0.86	81,724 shs	79,472 shs
ESPR Esperion Therapeutics	$0.78 -2.3%	$1.22	$0.73 ▼ $3.94	$154.70M	0.75	5.50 million shs	5.92 million shs
PRAN Alterity Therapeutics	$4.15 -5.5%	$1.41	$1.09 ▼ $2.91	$36.94M	1.05	130,956 shs	27,866 shs
TNGX Tango Therapeutics	$1.40 +6.9%	$1.48	$1.03 ▼ $12.02	$151.35M	1.02	1.08 million shs	993,029 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	-7.47%	-3.59%	+4.81%	+21.07%	+77.03%
ESPR Esperion Therapeutics	-2.28%	-19.97%	-23.46%	-58.47%	-64.99%
PRAN Alterity Therapeutics	-8.54%	+0.92%	+40.03%	+1.15%	+112.08%
TNGX Tango Therapeutics	+6.87%	+11.11%	-0.71%	-43.09%	-80.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DERM Journey Medical	2.2329 of 5 stars	3.6	2.0	0.0	0.0	2.1	1.7	0.6
ESPR Esperion Therapeutics	3.5688 of 5 stars	3.3	2.0	0.0	3.9	1.5	1.7	0.6
PRAN Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	1.656 of 5 stars	3.5	0.0	0.0	0.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	3.20	Buy	$9.88	56.25% Upside
ESPR Esperion Therapeutics	2.50	Moderate Buy	$6.25	700.56% Upside
PRAN Alterity Therapeutics	0.00	N/A	N/A	N/A
TNGX Tango Therapeutics	3.00	Buy	$12.33	780.95% Upside

Current Analyst Ratings Breakdown

Latest PRAN, ESPR, DERM, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/14/2025	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/27/2025	DERM Journey Medical	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$10.50
3/27/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/20/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/4/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$56.13M	2.60	$0.22 per share	28.37	$1.05 per share	6.02
ESPR Esperion Therapeutics	$259.57M	0.60	N/A	N/A	($3.85) per share	-0.20
PRAN Alterity Therapeutics	$150K	246.23	N/A	N/A	$1.40 per share	2.96
TNGX Tango Therapeutics	$42.07M	3.60	N/A	N/A	$2.48 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$3.85M	-$0.74	N/A	N/A	N/A	-31.74%	-132.10%	-26.90%	5/14/2025 (Estimated)
ESPR Esperion Therapeutics	-$209.25M	-$0.80	N/A	N/A	N/A	-29.37%	N/A	-10.77%	N/A
PRAN Alterity Therapeutics	-$6.40M	-$0.70	N/A	∞	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	-$101.74M	-$1.21	N/A	N/A	N/A	-284.42%	-49.64%	-32.00%	N/A

Latest PRAN, ESPR, DERM, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DERM Journey Medical	-$0.24	N/A	N/A	N/A	$12.05 million	N/A
5/12/2025	Q1 2025	TNGX Tango Therapeutics	-$0.34	-$0.36	-$0.02	-$0.36	$6.73 million	$5.39 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million
3/26/2025	Q4 2024	DERM Journey Medical	-$0.22	$0.08	+$0.30	$0.08	$14.21 million	$14.30 million
2/27/2025	Q4 2024	TNGX Tango Therapeutics	-$0.32	-$0.35	-$0.03	-$0.35	$7.84 million	$4.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAN Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	1.81	1.38	1.03
ESPR Esperion Therapeutics	N/A	1.85	1.37
PRAN Alterity Therapeutics	N/A	4.37	N/A
TNGX Tango Therapeutics	N/A	8.00	8.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
ESPR Esperion Therapeutics	47.39%
PRAN Alterity Therapeutics	3.63%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	13.16%
ESPR Esperion Therapeutics	1.00%
PRAN Alterity Therapeutics	38.80%
TNGX Tango Therapeutics	6.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	23.10 million	18.14 million	N/A
ESPR Esperion Therapeutics	200	198.15 million	195.07 million	Optionable
PRAN Alterity Therapeutics	14	8.90 million	N/A	Not Optionable
TNGX Tango Therapeutics	90	108.11 million	100.65 million	Optionable

PRAN, ESPR, DERM, and TNGX Headlines

Recent News About These Companies

Tango Therapeutics (NASDAQ:TNGX) Posts Earnings Results, Misses Estimates By $0.02 EPS

May 14 at 7:54 AM | marketbeat.com

Analyzing Tango Therapeutics (NASDAQ:TNGX) and Rosetta Genomics (OTCMKTS:ROSGQ)

May 14 at 1:21 AM | americanbankingnews.com

Tango Therapeutics Reports Q1 2025 Financial Results and Updates on TNG462 and Pipeline Developments

May 14 at 12:55 AM | nasdaq.com

Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13 at 2:40 AM | finanznachrichten.de

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 13 at 2:40 AM | finance.yahoo.com

Tango Therapeutics Extends Cash Runway Amid Clinical Progress

May 13 at 12:08 AM | tipranks.com

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates

May 12 at 9:15 AM | zacks.com

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 12 at 7:00 AM | globenewswire.com

Analysts Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $12.33

May 12 at 1:25 AM | americanbankingnews.com

4,000,000 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Bought by Farallon Capital Management LLC

May 11 at 7:40 AM | marketbeat.com

Balyasny Asset Management L.P. Has $10.13 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 11 at 5:30 AM | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of "Buy" by Analysts

May 11 at 2:12 AM | marketbeat.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Monday

May 7, 2025 | marketbeat.com

Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

May 5, 2025 | zacks.com

Boxer Capital Management LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 4, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Makes New Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 4, 2025 | marketbeat.com

TCG Crossover Management LLC Invests $33.17 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)

May 1, 2025 | marketbeat.com

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 1, 2025 | globenewswire.com

Nantahala Capital Management LLC Invests $8.67 Million in Tango Therapeutics, Inc. (NASDAQ:TNGX)

April 30, 2025 | marketbeat.com

T. Rowe Price Investment Management Inc. Trims Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX)

April 30, 2025 | marketbeat.com

Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.37%

April 29, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAN, ESPR, DERM, and TNGX Company Descriptions

Journey Medical NASDAQ:DERM

$6.32 -0.51 (-7.47%)

As of 05/13/2025 04:00 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Esperion Therapeutics NASDAQ:ESPR

$0.78 -0.02 (-2.28%)

Closing price 05/13/2025 04:00 PM Eastern

Extended Trading

$0.78 0.00 (-0.60%)

As of 07:36 AM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Alterity Therapeutics NASDAQ:PRAN

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Tango Therapeutics NASDAQ:TNGX

$1.40 +0.09 (+6.87%)

Closing price 05/13/2025 04:00 PM Eastern

Extended Trading

$1.38 -0.02 (-1.43%)

As of 07:00 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time